Phase III results for Almirall's Eklira prompt plans for 2010 COPD filing
10 September 2009
Asher Mullard
Please Login to read the full article.
10 September 2009
Asher Mullard
asher.mullard@informa.com
Almirall's Eklira (aclidinium bromide) has a good onset of action time and improves exercise endurance in COPD patients, show two confirmatory Phase III trials, prompting the company to announce plans to file the drug with the EMEA in early 2010.
Like Boehringer Ingelheim/Pfizer's approved...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Pearl's COPD drug blows Foradil, Spiriva away in lung function
- Pearl on track for 2012 pivotal COPD studies thanks to Phase IIb progress
- Japanese COPD alliance with Novartis marks new ground for Eisai
- European filing of Seebri Breezhaler triggers $5m from Novartis for Vectura
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
